Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

a Multicentre, Double-blind, Randomized, Placebo-controlled Phase III Trial of the Inhaled β2-adrenergic Receptor Agonist Salbutamol for Transient Tachypnoea of the Newborn (the REFSAL Trial)

NCT05527704 is registered in ClinicalTrials.gov with Medical University of Warsaw as lead sponsor.

NCT NCT05527704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05527704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
a Multicentre, Double-blind, Randomized, Placebo-controlled Phase III Trial of the Inhaled β2-adrenergic Receptor Agonist Salbutamol for Transient Tachypnoea of the Newborn (the REFSAL Trial)
Lead sponsor
Medical University of Warsaw
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 31, 2021
Completion date
September 30, 2026
Enrollment
608 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pphn, respiratory failure, ttn